Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

The development of immune checkpoint blockade (ICB) therapies has been instrumental in advancing the field of immunotherapy. Despite the prominence of these treatments, many patients exhibit primary or acquired resistance, rendering them ineffective. For example, anti-programmed cell death protein 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Laubach, Kyra, Turan, Tolga, Mathew, Rebecca, Wilsbacher, Julie, Engelhardt, John, Samayoa, Josue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571065/
https://www.ncbi.nlm.nih.gov/pubmed/37842241
http://dx.doi.org/10.20517/cdr.2023.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571065/
https://www.ncbi.nlm.nih.gov/pubmed/37842241
http://dx.doi.org/10.20517/cdr.2023.60

Ejemplares similares